Hear from your peers

Novo Nordisk is committed to providing information to help HCPs as they navigate through understanding what Tresiba® may offer their patients with diabetes. Below are videos and articles that were created to demonstrate why experts in the field have chosen to prescribe Tresiba®.

Smiling Doctor

TRESIBA® SPEAKER SERIES

Industry leader James R. Gavin, III, MD, PhD, discusses the clinical pharmacology of Tresiba®.


Doctor with glasses

SEE BEYOND THE CHARTS

Michael Heile, MD, examines 3 real case studies of patients with diabetes.


Two doctors

BASAL INSIGHTS

Steven Edelman, MD, and Stephen Brunton, MD, discuss key topics related to Tresiba® in this article and video series.

Tresiba® Speaker Series

with James R. Gavin, III, MD, PhD


The Tresiba® Speaker Series features industry leader Dr Gavin covering the clinical pharmacology of Tresiba®, including the mechanism of protraction and duration of action.

AT THE MOLECULAR LEVEL

Dr Gavin examines the mechanism of protraction of Tresiba®, and how the basal insulin’s molecular makeup contributes to its long duration of action.

DURATION OF ACTION

Dr Gavin discusses the pharmacokinetics behind the long duration of action of Tresiba®, and what it means for patients with diabetes.

See Beyond the Charts

with Michael Heile, MD


In See Beyond the Charts, Dr Heile examines 3 real case studies of patients with diabetes. Dr Heile explains why Tresiba® was right for each patient, and why he often prescribes Tresiba® in his own practice.

RICK’S JOURNEY TO REACH HIS A1C GOAL

Dr Michael Heile examines a type 2 diabetes patient’s specific dosing and device needs, and why Tresiba® was the right basal insulin to help him lower his A1C.

HOW AN INSULIN PEN MADE A DIFFERENCE FOR MANDY

Dr Michael Heile examines a late onset type 1 diabetes patient’s case study, and why she and her nurse practitioner made the switch from an insulin pump to once-daily Tresiba®.

BEN, THE BROADWAY LIFE, AND BASAL INSULIN

Dr Michael Heile discusses Tresiba®, a long-acting basal insulin, and the clear guidance he gives busy patients like Ben, a professional actor and dancer, if they miss an insulin dose.

Basal Insights


In the Basal Insights article and video series, diabetes-care experts discuss key topics related to prescribing Tresiba® for adult patients, featuring endocrinologist Dr Steven Edelman and primary care physician Dr Stephen Brunton.

AN ENDOCRINOLOGIST’S POINT OF VIEW

Dr Edelman explores the efficacy and safety of Tresiba®.

PRIMARY CARE PERSPECTIVE

Primary care physician Dr Brunton on the Tresiba® duration of action.

INSULIN PENS AND PRIMARY CARE

Dr Brunton gives his take on prescribing Tresiba® FlexTouch®.

Selected Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening

Indications and Usage

Tresiba® (insulin degludec injection) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis or for pediatric patients requiring less than 5 units of Tresiba®.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine)

Please click here for Prescribing Information.